ArticleThe Journal of clinical investigation2021
Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City.
Article in The Journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis.The Journal of infection · 2022Pooled it
- Real-Word Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2022Pooled it
- Cycle threshold values and SARS-CoV-2 variant associations with breakthrough infections: a retrospective study in Accra, Ghana.BMC infectious diseases · 2025Article
- SARS-CoV-2 Variants: Genetic Insights, Epidemiological Tracking, and Implications for Vaccine Strategies.International journal of molecular sciences · 2025Review
- Article
- Community-level variability in Bronx COVID-19 hospitalizations associated with differing population immunity during the second year of the pandemic.Virus evolution · 2024Article
- Generation of quality-controlled SARS-CoV-2 variant stocks.Nature protocols · 2023Review
- Article
- Variant-specific introduction and dispersal dynamics of SARS-CoV-2 in New York City - from Alpha to Omicron.PLoS pathogens · 2023Article
- Article
- COVID-19 vaccination and case fatality rates: a case report in a Brazilian municipality.Cadernos de saude publica · 2023Article
- Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers.Human vaccines & immunotherapeutics · 2022Article
- Article
- B cell receptor signatures associated with strong and poor SARS-CoV-2 vaccine responses.Emerging microbes & infections · 2022Article
- In vitro inhibition of SARS-CoV-2 Infection by dry algae powders.Scientific reports · 2022Article
- Multifaceted Assessment of Wastewater-Based Epidemiology for SARS-CoV-2 in Selected Urban Communities in Davao City, Philippines: A Pilot Study.International journal of environmental research and public health · 2022Article
- SARS-CoV-2 variants and vulnerability at the global level.Journal of medical virology · 2022Review
- Remdesivir resistance in transplant recipients with persistent COVID-19.Research square · 2022Article
- Recapping the Features of SARS-CoV-2 and Its Main Variants: Status and Future Paths.Journal of personalized medicine · 2022Review
- Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences.Vaccines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
The efficacy of COVID-19 mRNA vaccines is high, but breakthrough infections still occur. We compared the SARS-CoV-2 genomes of 76 breakthrough cases after full vaccination with BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna), or JNJ-78436735 (Janssen) to unvaccinated controls (February-April 2021) in metropolitan New York, including their phylogenetic relationship, distribution of variants, and full spike mutation profiles. The median age of patients in the study was 48 years; 7 required hospitalization and 1 died. Most breakthrough infections (57/76) occurred with B.1.1.7 (Alpha) or B.1.526 (Iota). Among the 7 hospitalized cases, 4 were infected with B.1.1.7, including 1 death. Both unmatched and matched statistical analyses considering age, sex, vaccine type, and study month as covariates supported the null hypothesis of equal variant distributions between vaccinated and unvaccinated in χ2 and McNemar tests (P > 0.1), highlighting a high vaccine efficacy against B.1.1.7 and B.1.526. There was no clear association among breakthroughs between type of vaccine received and variant. In the vaccinated group, spike mutations in the N-terminal domain and receptor-binding domain that have been associated with immune evasion were overrepresented. The evolving dynamic of SARS-CoV-2 variants requires broad genomic analyses of breakthrough infections to provide real-life information on immune escape mediated by circulating variants and their spike mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.